Pharmacokinetics of a slow-release preparation of ketoprofen lysine in man.
The lysine salt of 2-(3-benzoylphenyl)propionic acid (ketoprofen lysine) was administered at the dose of 160 mg either in two conventional capsules (Artrosilene) or in one slow-release capsule in a randomized sequence to 8 volunteers. Serum and urine concentrations of ketoprofen were determined by HPLC. The slow-release preparation had a bioavailability greater than 90% as compared with the conventional capsule and produced lower and longer lasting ketoprofen serum levels. These results suggest that two daily administrations of the new formulation should be suitable for therapeutic use.
D000328:Adult; D001682:Biological Availability; D003692:Delayed-Action Preparations; D006801:Humans; D007660:Ketoprofen / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism* / Q000652:urine; D007700:Kinetics; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000378:metabolism*
D003692:Delayed-Action Preparations; D010666:Phenylpropionates; C029946:ketoprofen lysine; D007660:Ketoprofen; D008239:Lysine